Company / Cash & Equivalents
IDEAYA Biosciences, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$112.8M
FY2025
5-year range
$72.0M / $157.0M
FY2021-FY2025
Trend
+33.7%
vs FY2024
Sector context
#133 of 207
Health Care
What the data says
At $113M, IDEAYA Biosciences, Inc.'s cash & equivalents ranks #133 of 207 in the Health Care sector. Declined from $157M to $113M over the past 2 years.
Based on SEC 10-K filings.
$113M in FY2025 with a 5-year CAGR of +27.1%.
Declined from $157M to $113M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +7.0%
- 5-Year CAGR
- +27.1%
- 10-Year CAGR
- -
Sector benchmark
#133 of 207 in Health CareTop 64% of 207This company $112.8M Sector average $669.5M
▼
-83.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +27.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 33.7% year-over-year.
- Ranks #133 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 4.55 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $112.8M | +33.7% |
| FY2024 | $84.4M | -46.3% |
| FY2023 | $157.0M | +70.6% |
| FY2022 | $92.0M | +27.8% |
| FY2021 | $72.0M | +111.5% |
| FY2020 | $34.1M | +0.0% |
| FY2019 | $34.1M | +66.1% |
| FY2018 | $20.5M | +244.0% |
| FY2017 | $6.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026